Report Detail

Service & Software Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth (Status and Outlook) 2023-2029

  • RnM4502222
  • |
  • 17 January, 2023
  • |
  • Global
  • |
  • 104 Pages
  • |
  • LPI(LP Information)
  • |
  • Service & Software

The global Eosinophilic Granulomatosis with Polyangiitis Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Eosinophilic Granulomatosis with Polyangiitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Eosinophilic Granulomatosis with Polyangiitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Eosinophilic Granulomatosis with Polyangiitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Eosinophilic Granulomatosis with Polyangiitis Treatment players cover Teva Pharmaceutical Industries, GlaxoSmithKline, Genentech, Baxter Healthcare, F. Hoffmann-La Roche, Cephalon, Amgen, Sanofi S.A. and Koninklijke DSM N.V, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Eosinophilic Granulomatosis with Polyangiitis Treatment Industry Forecast” looks at past sales and reviews total world Eosinophilic Granulomatosis with Polyangiitis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Eosinophilic Granulomatosis with Polyangiitis Treatment sales for 2023 through 2029. With Eosinophilic Granulomatosis with Polyangiitis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Eosinophilic Granulomatosis with Polyangiitis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Eosinophilic Granulomatosis with Polyangiitis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eosinophilic Granulomatosis with Polyangiitis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Eosinophilic Granulomatosis with Polyangiitis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eosinophilic Granulomatosis with Polyangiitis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eosinophilic Granulomatosis with Polyangiitis Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Eosinophilic Granulomatosis with Polyangiitis Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:
Segmentation by type
Steroids
Immunosuppressant
Biologics
Immune Globulins

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva Pharmaceutical Industries
GlaxoSmithKline
Genentech
Baxter Healthcare
F. Hoffmann-La Roche
Cephalon
Amgen
Sanofi S.A.
Koninklijke DSM N.V
AstraZeneca
Novartis International AG


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2018-2029
    • 2.1.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
  • 2.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Segment by Type
    • 2.2.1 Steroids
    • 2.2.2 Immunosuppressant
    • 2.2.3 Biologics
    • 2.2.4 Immune Globulins
  • 2.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type
    • 2.3.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
    • 2.3.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)
  • 2.4 Eosinophilic Granulomatosis with Polyangiitis Treatment Segment by Application
    • 2.4.1 Hospitals
    • 2.4.2 Clinics
    • 2.4.3 Others
  • 2.5 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application
    • 2.5.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
    • 2.5.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)

3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Player

  • 3.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Players
    • 3.1.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Players (2018-2023)
    • 3.1.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Players (2018-2023)
  • 3.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Eosinophilic Granulomatosis with Polyangiitis Treatment by Regions

  • 4.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Regions (2018-2023)
  • 4.2 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth (2018-2023)
  • 4.3 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth (2018-2023)
  • 4.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth (2018-2023)
  • 4.5 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth (2018-2023)

5 Americas

  • 5.1 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2018-2023)
  • 5.2 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023)
  • 5.3 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2018-2023)
  • 6.2 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023)
  • 6.3 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment by Country (2018-2023)
  • 7.2 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023)
  • 7.3 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment by Region (2018-2023)
  • 8.2 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023)
  • 8.3 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast

  • 10.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Regions (2024-2029)
    • 10.1.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Regions (2024-2029)
    • 10.1.2 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast
    • 10.1.3 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast
    • 10.1.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast
    • 10.1.5 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast
  • 10.2 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Country (2024-2029)
    • 10.2.1 United States Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.2.2 Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.2.3 Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.2.4 Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
  • 10.3 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Region (2024-2029)
    • 10.3.1 China Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.3.2 Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.3.3 Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.3.4 Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.3.5 India Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.3.6 Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
  • 10.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Country (2024-2029)
    • 10.4.1 Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.4.2 France Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.4.3 UK Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.4.4 Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.4.5 Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
  • 10.5 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Region (2024-2029)
    • 10.5.1 Egypt Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.5.2 South Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.5.3 Israel Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.5.4 Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
    • 10.5.5 GCC Countries Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
  • 10.6 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Type (2024-2029)
  • 10.7 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Application (2024-2029)

11 Key Players Analysis

  • 11.1 Teva Pharmaceutical Industries
    • 11.1.1 Teva Pharmaceutical Industries Company Information
    • 11.1.2 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.1.3 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.1.4 Teva Pharmaceutical Industries Main Business Overview
    • 11.1.5 Teva Pharmaceutical Industries Latest Developments
  • 11.2 GlaxoSmithKline
    • 11.2.1 GlaxoSmithKline Company Information
    • 11.2.2 GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.2.3 GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.2.4 GlaxoSmithKline Main Business Overview
    • 11.2.5 GlaxoSmithKline Latest Developments
  • 11.3 Genentech
    • 11.3.1 Genentech Company Information
    • 11.3.2 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.3.3 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.3.4 Genentech Main Business Overview
    • 11.3.5 Genentech Latest Developments
  • 11.4 Baxter Healthcare
    • 11.4.1 Baxter Healthcare Company Information
    • 11.4.2 Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.4.3 Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.4.4 Baxter Healthcare Main Business Overview
    • 11.4.5 Baxter Healthcare Latest Developments
  • 11.5 F. Hoffmann-La Roche
    • 11.5.1 F. Hoffmann-La Roche Company Information
    • 11.5.2 F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.5.3 F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.5.4 F. Hoffmann-La Roche Main Business Overview
    • 11.5.5 F. Hoffmann-La Roche Latest Developments
  • 11.6 Cephalon
    • 11.6.1 Cephalon Company Information
    • 11.6.2 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.6.3 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.6.4 Cephalon Main Business Overview
    • 11.6.5 Cephalon Latest Developments
  • 11.7 Amgen
    • 11.7.1 Amgen Company Information
    • 11.7.2 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.7.3 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.7.4 Amgen Main Business Overview
    • 11.7.5 Amgen Latest Developments
  • 11.8 Sanofi S.A.
    • 11.8.1 Sanofi S.A. Company Information
    • 11.8.2 Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.8.3 Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.8.4 Sanofi S.A. Main Business Overview
    • 11.8.5 Sanofi S.A. Latest Developments
  • 11.9 Koninklijke DSM N.V
    • 11.9.1 Koninklijke DSM N.V Company Information
    • 11.9.2 Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.9.3 Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.9.4 Koninklijke DSM N.V Main Business Overview
    • 11.9.5 Koninklijke DSM N.V Latest Developments
  • 11.10 AstraZeneca
    • 11.10.1 AstraZeneca Company Information
    • 11.10.2 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.10.3 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.10.4 AstraZeneca Main Business Overview
    • 11.10.5 AstraZeneca Latest Developments
  • 11.11 Novartis International AG
    • 11.11.1 Novartis International AG Company Information
    • 11.11.2 Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
    • 11.11.3 Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
    • 11.11.4 Novartis International AG Main Business Overview
    • 11.11.5 Novartis International AG Latest Developments

12 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Eosinophilic Granulomatosis with Polyangiitis Treatment. Industry analysis & Market Report on Eosinophilic Granulomatosis with Polyangiitis Treatment is a syndicated market report, published as Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth (Status and Outlook) 2023-2029. It is complete Research Study and Industry Analysis of Eosinophilic Granulomatosis with Polyangiitis Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
2,898.72
5,797.44
3,389.16
6,778.32
553,941.00
1,107,882.00
305,244.00
610,488.00
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report